Laurent Fischer - 22 Oct 2026 Form 3 Insider Report for Lycia Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 22 Oct 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 22 Oct 2026, 19:19:52 UTC
Prior SEC filing: 11 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy Bachrodt, Attorney-in-Fact

Filing notes and source

Key filing fact

Laurent Fischer filed Form 3 for Lycia Therapeutics, Inc. on 22 Oct 2026.

Key facts

This page summarizes Laurent Fischer's Form 3 filing for Lycia Therapeutics, Inc..
0 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 22 Oct 2026, 19:19.

Change

Previous filing in this sequence was filed on 11 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001379344 Primary reporting owner

Fischer Laurent

Relationship: Director
Address: C/O LYCIA THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 200, SOUTH SAN FRANCISCO
Signature: /s/ Amy Bachrodt, Attorney-in-Fact
Signature date: 22 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 33,269
Date: 22 Oct 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 22 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,307
Exercise price: $2.44
Footnotes: F1

No ticker holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 22 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,307
Exercise price: $3.70
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F2

The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.